POLA1
DNA polymerase alpha catalytic subunit
As of the edition of 20 October 2026, POLA1 (DNA polymerase alpha catalytic subunit, UniProt P09884) has 3 drugs tested at it and 5 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09884
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 21
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Inherited and neonatal
- Registered trials of its drugs
- 1,156
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fludarabine | Marketed | Phase 4 | none listed |
| TAR-200 | Active | Phase 3 | none listed |
| FF-10832 | Active | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 3 |
| Total on the list | 5 |
The other 3 companies at POLA1
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at POLA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.